180 Life Sciences [ATNF] vs Blueprint Medicines [BPMC] Detailed Stock Comparison

180 Life Sciences Corp.

NASDAQ
Loading...

Blueprint Medicines Corp.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: 180 Life Sciences Corp. wins in 9 metrics, Blueprint Medicines Corp. wins in 6 metrics, with 1 ties. 180 Life Sciences Corp. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric 180 Life Sciences Corp. Blueprint Medicines Corp. Better
P/E Ratio (TTM) 0.11 -120.99 180 Life Sciences Corp.
Price-to-Book Ratio 7.90 24.43 180 Life Sciences Corp.
Debt-to-Equity Ratio 26.25 208.50 180 Life Sciences Corp.
PEG Ratio 0.00 -137.72 Tie
EV/EBITDA -6.81 -53.14 180 Life Sciences Corp.
Profit Margin (TTM) 0.00% -27.70% 180 Life Sciences Corp.
Operating Margin (TTM) 0.00% -27.50% 180 Life Sciences Corp.
Return on Equity -371.02% -47.71% Blueprint Medicines Corp.
Return on Assets (TTM) -55.46% -9.75% Blueprint Medicines Corp.
Free Cash Flow (TTM) $-1.48M $-197.22M 180 Life Sciences Corp.
1-Year Return 234.00% 12.60% 180 Life Sciences Corp.
Price-to-Sales Ratio (TTM) N/A 14.89 N/A
Enterprise Value $43.94M $8.42B Blueprint Medicines Corp.
EV/Revenue Ratio N/A 14.97 N/A
Gross Profit Margin (TTM) N/A 98.12% N/A
Revenue per Share (TTM) $0 $9 Blueprint Medicines Corp.
Earnings per Share (Diluted) $-14.95 $-2.51 Blueprint Medicines Corp.
Beta (Stock Volatility) 0.41 0.83 180 Life Sciences Corp.
Short % of Float 47.16% 5.45% Blueprint Medicines Corp.

180 Life Sciences Corp. vs Blueprint Medicines Corp. Stock Performance Analysis

Loading Price Chart...

ATNF
BPMC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
180 Life Sciences Corp.0.60%748.48%633.62%818.03%1,766.67%2,000.00%
Blueprint Medicines Corp.0.00%0.12%1.05%53.79%61.42%61.42%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
180 Life Sciences Corp.234.00%-91.14%-99.60%-99.54%-99.54%-99.54%
Blueprint Medicines Corp.12.60%149.54%73.38%370.76%598.65%598.65%

Performance & Financial Health Analysis: 180 Life Sciences Corp. vs Blueprint Medicines Corp.

MetricATNFBPMC
Market Information
Market Cap i$2.57B$8.37B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i11,607,0045,799,940
90 Day Avg. Volume i10,978,7434,343,357
Last Close$16.80$129.46
52 Week Range$0.66 - $23.05$73.04 - $129.65
% from 52W High-27.11%-0.15%
All-Time High$4,957.10 (Apr 12, 2021)$129.65 (Jul 16, 2025)
% from All-Time High-99.66%-0.15%
Growth Metrics
Quarterly Revenue GrowthN/A0.56%
Quarterly Earnings GrowthN/A-0.99%
Financial Health
Profit Margin (TTM) i0.00%-0.28%
Operating Margin (TTM) i0.00%-0.28%
Return on Equity (TTM) i-3.71%-0.48%
Debt to Equity (MRQ) i26.25208.50
Cash & Liquidity
Book Value per Share (MRQ)$0.89$5.30
Cash per Share (MRQ)$0.37$8.92
Operating Cash Flow (TTM) i$-3,159,107$-145,552,000
Levered Free Cash Flow (TTM) i$-3,003,669$-20,779,750
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: 180 Life Sciences Corp. vs Blueprint Medicines Corp.

MetricATNF (Oct 21, 2025)BPMC (Aug 03, 2025)
Price Ratios
P/E Ratio (TTM) i0.11-120.99
Forward P/E i-15.30-137.72
PEG Ratio i0.00-137.72
Price to Sales (TTM) iN/A14.89
Price to Book (MRQ) i7.9024.43
Market Capitalization
Market Capitalization i$2.57B$8.37B
Enterprise Value i$43.94M$8.42B
Enterprise Value Metrics
Enterprise to Revenue iN/A14.97
Enterprise to EBITDA i-6.81-53.14
Risk & Other Metrics
Beta i0.410.83
Book Value per Share (MRQ) i$0.89$5.30

Financial Statements Comparison: 180 Life Sciences Corp. vs Blueprint Medicines Corp.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricATNF (2024)BPMC (2024)
Revenue/Sales i0508.82M
Cost of Goods Sold iN/A20.16M
COGS % of Revenue i-4.0%
Gross Profit iN/A488.66M
Gross Margin i-96.0%
Research & Development i1.97M341.43M
Operating Income (EBIT) i-6.32M-212.04M
Operating Margin i--41.7%
EBITDA i-4.83M-154.44M
EBITDA Margin i--30.4%
Pre-Tax Income i-6.46M-65.86M
Pre-Tax Income % of Revenue i--12.9%
Income Tax i-296,0241.23M
Income Tax % of Revenue i-0.2%
Net Income (Profit) i-6.17M-67.09M
Profit Margin i--13.2%

Balance Sheet & Liquidity Metrics

MetricATNF (2024)BPMC (2024)
Cash & Equivalents i4.59M102.01M
Total Current Assets i5.14M742.68M
Total Current Assets % of Revenue i-146.0%
Total Current Liabilities i3.50M260.80M
Total Current Liabilities % of Revenue i-51.3%
Long-Term Debt i6,616411.84M
Long-Term Debt % of Revenue i-80.9%
Total Shareholders Equity i9.25M298.67M
Retained Earnings i-141.52M-2.41B
Retained Earnings % of Revenue i--473.1%
Property, Plant & Equipment iN/A89.90M

Cash Flow Statement Comparison

MetricATNF (2024)BPMC (2024)
Operating Cash Flow i-4.57M-2.02M
Operating Cash Flow % of Revenue i--0.4%
Capital Expenditures iN/A-4.63M
Free Cash Flow i-1.48M-197.22M
FCF Margin i--38.8%
Debt Repayment i-1.33MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricATNFBPMC
Shares Short i1.14M3.13M
Short Ratio i0.190.62
Short % of Float i47.16%5.45%
Shares Outstanding i6.04M63.71M
Float Shares i5.04M60.00M
% Held by Insiders i9.99%0.88%
% Held by Institutions i0.06%109.19%
% Held by Public i89.95%-10.07%

Dividend Analysis & Yield Comparison: 180 Life Sciences Corp. vs Blueprint Medicines Corp.

MetricATNFBPMC
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A